Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. The company's lead product candidate is the selonabant, a small-molecule antagonist of cannabinoid binding receptor type-1(CB1), which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Lakeway, Texas.
| Business Activity | PASS |
| Debt Ratio (0.00%) | PASS |
| Cash Ratio (0.43%) | FAIL |
| Receivables Ratio (0.00%) | PASS |
| Revenue Ratio (0.00%) | PASS |
| Overall | FAIL |
| Date | EPS Est. | Reported EPS | Surprise % |
|---|---|---|---|
| 2025-11-13 | -0.12 | -0.05 | +58.3% |
| 2025-09-29 | -0.05 | -0.05 | -- |
| 2025-09-24 | -0.05 | Pending | -- |
| 2025-05-13 | -0.05 | -0.04 | +20.0% |
| 2025-02-14 | -0.08 | -0.09 | -12.5% |
| 2024-11-13 | -0.05 | -0.08 | -60.0% |
| 2024-09-25 | -0.11 | -0.05 | +54.5% |
| 2024-05-15 | -0.12 | -0.06 | +50.0% |
| Period | Revenue | Net Income | EBITDA | Gross Profit | Op. Income | EPS |
|---|---|---|---|---|---|---|
| 2025-12-31 | — | -$2.0M | -$2.0M | — | -$2.1M | -0.05 |
| 2025-09-30 | — | -$2.2M | -$2.1M | — | -$2.3M | -0.05 |
| 2025-06-30 | — | -$2.1M | -$2.1M | — | -$2.2M | -0.05 |
| 2025-03-31 | — | -$1.7M | -$1.4M | — | -$1.5M | -0.04 |
| 2024-12-31 | — | -$2.5M | -$2.4M | — | -$2.4M | -0.09 |
| Date | Name | Role | Shares | Value |
|---|---|---|---|---|
| 2024-12-23 | ENGLISH ARON R | Director and Beneficial Owner of more than 10% of a Class of Security | 10,101,010 | $12.6M |
| Holder | Shares | Value | % Held |
|---|---|---|---|
| Morgan Stanley | 399.4K | $183.7K | 0.0% |
| Bank of America Corporation | 382.0 | $175.0 | — |
$9.7M
2.38
-1.936
1.50
0.0%
2
A single score combining all analytical layers below. A is strongest, D is weakest.
How much could this ticker lose on a bad day? These metrics measure worst-case scenarios from historical data.
Based on 10,000 simulated price paths, here is the probability of where this ticker could be in 30, 60, and 90 days.
What direction is this ticker actually moving, filtered through noise? Is it speeding up or slowing down?
Classic chart signals that institutional traders monitor. Golden Cross is bullish, Death Cross is bearish.
Is this company financially sound? The Z-Score measures bankruptcy risk. The F-Score measures fundamental strength.
These tickers tend to move together (positive) or in opposite directions (negative). Useful for portfolio diversification.
| Ticker | Correlation |
|---|---|
| ABVX | 0.292 |
| SHAW.L | 0.232 |
| FUJHY | 0.182 |
| KEGX | 0.176 |
| NWS | 0.175 |
| Ticker | Correlation |
|---|---|
| IQCD.QA | -0.164 |
| MPLT | -0.163 |
| UFC.AE | -0.152 |
| SANAM.KW | -0.152 |
| AFNIC.AB | -0.148 |
Does this ticker have consistent patterns on certain days or months? Historical tendencies, not guarantees.
After this company beats earnings, does the price keep going up? Drift tracks post-earnings momentum.
How does this ticker's recent performance compare to the entire universe? Ranked across 1, 3, 6, and 12-month returns.